title: Transcatheter Aortic Valve Implantation Experience with SAPIEN 3.
abstract: Based on randomized trials with first generation devices, transcatheter aortic valve replacement (TAVI) has been included into the treatment strategy for high-risk and inoperable patients with severe aortic stenosis. Procedural complications remain a concern with TAVI, including stroke, vascular complications, paravalvular leak (PVL) and conduction disturbances. Addressing these limitations will support TAVI use in lower risk populations. This review discussed features and most recent clinical evidence of the new balloon-expandable THV (SAPIEN 3, Edwards Lifescience, Irvine, CA, USA).
authors.affiliation: Department of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy - mbarbanti83@gmail.com.
authors.forename: Y
authors.initials: Y
authors.lastname: Ohno
authors.forename: C
authors.initials: C
authors.lastname: Tamburino
authors.forename: M
authors.initials: M
authors.lastname: Barbanti
mesh_terms: D001024:Aortic Valve Stenosis / Q000473:pathology / Q000601:surgery*; D006350:Heart Valve Prosthesis; D006801:Humans; D011183:Postoperative Complications / Q000453:epidemiology; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D065467:Transcatheter Aortic Valve Replacement / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*